Oncorus, Inc. is a biopharmaceutical company that is developing viral immunotherapies for treating cancer patients. Using its oncolytic herpes simplex virus type 1 platform, the company has developed lead product candidate ONCR-177. The Cambridge, Massachusetts-based company is also developing other therapies, including ONCR-GBM, to treat brain cancer and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus.